Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short term Debt: 2020-2023

  • Zevra Therapeutics' Short term Debt was N/A to $37.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was $37.7 million, marking a year-over-year change of. This contributed to the annual value of $37.7 million for FY2023, which is N/A change from last year.
  • Per Zevra Therapeutics' latest filing, its Short term Debt stood at $37.7 million for Q4 2023, which was up 5,419.77% from $683,000 recorded in Q1 2021.
  • In the past 5 years, Zevra Therapeutics' Short term Debt ranged from a high of $37.7 million in Q4 2023 and a low of $390,000 during Q4 2020.
  • Moreover, its 2-year median value for Short term Debt was $19.2 million (2021), whereas its average is $19.2 million.